TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announced last year a sharpened focus in three areas: 1) developing safe and effective drug therapies for diseases where soft tissue calcification, or “calcium deposits,” is a dominant feature, 2) validating the Company’s antibody and antigen derived diagnostics to determine levels of calcification, and 3) scientific studies to determine the infectious nature of the calcifying nano particles (CNPs).
